VeCollal, developed by Corpowell, has secured an investment from Seventure Partners via Health for Life Capital to accelerate the global expansion of its biomimetic, plant-based collagen technology.WHO: VeCollal, developed by Belgian nutraceuticals group Corpowell, mimics the natural amino acid profile of human collagen one-to-one. According to the company, this bioidentical foundation distinguishes VeCollal from incomplete animal collagen and simple "collagen boosters" currently available on the market.WHY: VeCollal had already secured early momentum with strategic partnerships in the United States and Europe, including co-branding projects with prominent brands such as Feel, Ringana, Aroma-Zone, Solaray and Life Extension. The capital injection validates the biomimetic technology and accelerates global rollout.IN THEIR OWN WORDS: Tony Van Campen, CEO and founder of Corpowell, said, "For me, VeCollal is about removing the choice between ethics and results."Isabelle de Cremoux, CEO of Seventure Partners, said, “The VeCollal technology is not only substantially more CO2-efficient than animal collagen, but the company also has a scalable, B2B model with strong traction in the United States, Asia, and Europe. Our investment is intended to accelerate the global roll-out and establish VeCollal as the leading brand in biomimetic high-value, protein alternative ingredients.”DETAILS:VeCollal, developed by Corpowell, has secured an investment from Seventure Partners via Health for Life Capital.The company also announced a clinical breakthrough: the ingredient demonstrated a 20.1% reduction in visible cellulite, opening up the market to cosmetic companies.